Metformin use may enhance progression-free survival (PFS) in patients receiving first-line systemic therapy for patients with metastatic colorectal cancer.
Widespread noncompliance with federal cost-sharing rules exists, particularly impacting Medicare beneficiaries and patient-preferred prep options, study finds.
Early circulating tumor DNA (ctDNA) changes predict survival in mismatch repair or microsatellite instability–high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs).
Initiating fecal immunochemical test (FIT) screening before age 50 can significantly reduce colorectal cancer incidence and mortality, according to one study.